In the Press
What people are saying
about Assyro
Coverage from journalists, analysts, and ecosystem partners on how Assyro is rebuilding regulatory submissions for pharma, biotech, and medical device teams.
FeaturedProfile
SF Bay Area Times·January 14, 2026
Assyro AI: The Regulatory Copilot Transforming Pharma Submissions
“The path from clinical trials to FDA approval is paved with paperwork — and formatting mistakes can cause significant delays.”
By Sierra DelgadoRead the full article
More coverage
Montréal TimesFeature
Assyro AI Emerges from Antler Toronto to Transform Pharma Regulatory Submissions
“Pharmaceutical companies spend billions annually on regulatory compliance, with submission preparation often taking months of painstaking documentation work.”
Élodie TremblayJanuary 14, 2026
ReadTechBullionEcosystem
Antler Toronto is Fueling the Next Generation of AI Companies
“Antler Toronto's latest cohort is producing the next wave of AI-native companies — including Assyro, building for pharma regulatory.”
December 2, 2025
ReadCoverage links are curated from publicly indexed sources and updated on a rolling basis.